OMEICOS

Feedback from the U.S. Food and Drug Administration (FDA) supports acceleration of OMT-28's development path directly into a pivotal Phase 3 studyWith the vast majority of PMD patients having no FDA-approved therapeutic option, OMT-28 addresses a signific

Feedback from the U.S. Food and Drug Administration (FDA) supports acceleration of OMT-28's development path directly into a pivotal Phase 3 study With the vast majority of PMD patients having no FDA-approved therapeutic option, OMT-28 addresses a signifi

Meet us in Cologne, Germany, November 9 - 11, 2026 https://informaconnect.com/bioeurope/

Trial Results Support Transition into Late-Stage Development with Program Expected to be Phase 2b/3-ready in H2 2026 BERLIN, GERMANY, January 29, 2026 - OMEICOS, a clinical-stage biopharmaceutical company developing first-in-class small molecule therapeut

Trial Results Support Transition into Late-Stage Development with Program Expected to be Phase 2b/3-ready in H2 2026 BERLIN, GERMANY, January 29, 2026 - OMEICOS, a clinical-stage biopharmaceutical company developing first-in-class small molecule therapeut

Meet us in Anger, France, May 31- June 4 2026 https://www.euromit2026.eu

Omeicos Therapeutics completes enrollment in phase 2a PMD-OPTION study of OMT-28 in primary mitochondrial disease

Interim data confirms OMT-28's strong safety profile in PMD patients, top-line data expected mid-2025 BERLIN, GERMANY, September 26, 2024 - OMEICOS, a biopharmaceutical company developing first-in-class small molecule therapeutics, today announced the com

Development of robust 17,18-EEQ analogs as potential clinical antiarrhythmic agentsAdebesin et al. J Med Chem 2019VISIT Development of metabolically robust 17,18-EEQ analogsFalck et al. J Med Chem 2011VISIT

Cardioprotective effects of CYP-derived epoxymetabolites of docosahexaenoic acid involve limiting NLRP3 inflammasome activationDarwesh et al. Can J Physiol Pahrmacol 2019VISIT Novel Roles of Epoxyeicosanoids in Regulating Cardiac MitochondriaEl-Sikhry et